Telix Pharmaceuticals Limited (TLX:NASDAQ) closed at $11.16 on October 20, 2026, up 3.91% on the day. The stock trades 14.9% below its 52-week high of $13.11 and 77.7% above its 52-week low of $6.28. Over the past year, it gained 3.5%. Telix Pharmaceuticals Limited is part of the Health Care sector.
In 252 trading sessions since October 20, 2025, TLX closed higher on 125 days (50%). Its best day was February 20, 2026 (+14.61%) and its worst was September 21, 2026 (-10.17%). The stock moved 10% or more in a single session 3 times. It opened at least 5% above the previous day's high 3 times.
Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. Our mission is to be the global leader in radiopharmaceuticals by combining therapeutic and diagnostic modalities for the benefit of patients, an innovative precision medicine concept generally referred to as "theranostics". We have an extensive pipeline of theranostic radiopharmaceutical product candidates with a focus in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. Our theranostic approach is intended to use imaging and therapy together to "see and treat" cancer and rare diseases, to both better inform treatment decisions and deliver personalized therapy for patients.
Find more stocks like TLX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.